3SBio Inc.
三生製藥
- Listing
- HKEX 01530
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| SSGJ-707 | Clinical trials in China; first Phase 3 planned for 2025 | 2025-05-19 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2025-05-19 | Pfizer Inc. | SSGJ-707 | USD 1,250,000,000 | Clinical trials in China; first Phase 3 planned for 2025 |